Latest News: The ESMO-ESGO-ESP Consensus is advocating for the use of genomic instability tests validated in phase III trials Learn more
Participants have either:
Note: Patients with EPclin Risk Score <3.32867 will not be randomized, but will be followed annually for 10 years. All patients that have been tested with EndoPredict received chemotherapy.